Evidence map›Paper›PMID 36710966›Full record

ArticleFrontiers in cellular and infection microbiology2022

Investigation of microorganisms in cannabis after heating in a commercial vaporizer.

Danielle S Sopovski, Jing Han, Marla Stevens-Riley, Qiang Wang, Bruce D Erickson, Berk Oktem, Michelle Vanlandingham, Cassandra L Taylor, Steven L Foley

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Evaluation ofEnvironmental health perspectives · 2025
    Article
  3. Vaping ΔExpert review of clinical pharmacology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Danielle S SopovskiDivision of Microbiology, Food and Drug Administration (FDA) National Center for Toxicological Research, Jefferson, AR, United States.
Jing HanDivision of Microbiology, Food and Drug Administration (FDA) National Center for Toxicological Research, Jefferson, AR, United States.
Marla Stevens-RileyOffice of Pharmaceutical Quality, Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Silver Spring, MD, United States.
Qiang WangOffice of Pharmaceutical Quality, Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Silver Spring, MD, United States.
Bruce D EricksonDivision of Microbiology, Food and Drug Administration (FDA) National Center for Toxicological Research, Jefferson, AR, United States.
Berk OktemOffice of Science and Engineering Laboratories, Food and Drug Administration (FDA) Center for Devices and Radiological Health, Silver Spring, MD, United States.
Michelle VanlandinghamDivision of Biochemical Toxicology, Food and Drug Administration (FDA) National Center for Toxicological Research, Jefferson, AR, United States.
Cassandra L TaylorOffice of Pharmaceutical Quality, Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Silver Spring, MD, United States.
Steven L FoleyDivision of Microbiology, Food and Drug Administration (FDA) National Center for Toxicological Research, Jefferson, AR, United States.
National Center for Toxicological Research · USCenter for Drug Evaluation and Research · USOffice of Science · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There are concerns about microorganisms present on cannabis materials used in clinical settings by individuals whose health status is already compromised and are likely more susceptible to opportunistic infections from microbial populations present on the materials. Most concerning is administration by inhalation where cannabis plant material is heated in a vaporizer, aerosolized, and inhaled to receive the bioactive ingredients. Heating to high temperatures is known to kill microorganisms including bacteria and fungi; however, microbial death is dependent upon exposure time and temperature. It is unknown whether the heating of cannabis at temperatures and times designated by a commercial vaporizer utilized in clinical settings will significantly decrease the microbial loads in cannabis plant material. Methods: To assess this question, bulk cannabis plant material supplied by National Institute on Drug Abuse (NIDA) was used to assess the impact of heating by a commercial vaporizer. Initial method development studies using a cannabis placebo spiked with Results and discussion: Overall, while there were trends of reductions in microbial counts with heating, these reductions were not statistically significant, indicating that heating using standard vaporization parameters of 70 seconds at 190°C may not eliminate the existing microbial bioburden, including any opportunistic pathogens. When cultured organisms were identified by DNA sequence analyses, several fungal and bacterial taxa were detected in the different products that have been associated with opportunistic infections or allergic reactions including

Indexed as

CannabisHot TemperatureHumansNebulizers and VaporizersTemperaturecannabismetagenomicsmicrobial culturemicrobial populationsvaporizer

Identifiers

PMID36710966
PMCPMC9880168
OpenAlexW4315782690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.